Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2011
At a glance
- Drugs Doxepin (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Sponsors Somaxon Pharmaceuticals
- 20 May 2009 Results presented at the 162nd Annual Meeting of the American Psychiatric Association (APA 2009).
- 11 Jun 2008 New trial record.
- 07 May 2008 Results data have been reported in a Somaxon media release.